Plain-English translation of NCT06456684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This research study is following people who have early Parkinson's disease or are at high risk for developing it (prodromal phase). Researchers will use a special brain imaging scan called AV-133 PET imaging to see how the disease changes over time, along with regular clinical exams and blood tests. The goal is to better understand how Parkinson's disease progresses in its earliest stages.
Right now, doctors don't have many ways to track how Parkinson's disease develops in its earliest phases. By studying this imaging technique alongside clinical symptoms, researchers hope to find better markers for disease progression that could help guide treatment decisions and develop new therapies sooner.
You likely qualify if…
You likely don't qualify if…
You will visit the research center at baseline and then once every 12 months for about 2 years. At each visit, you'll have a brain imaging scan (PET scan), take clinical tests to check your motor and cognitive symptoms, and provide blood or other biological samples for analysis. The screening period lasts about 2 months, followed by 24 months of active follow-up, with most visits lasting a few hours.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Xuanwu Hospital, Beijing
Collaborators
Michael J. Fox Foundation for Parkinson's Research, XingImaging, LLC
Enrollment target
~76 participants
Started
April 2024
Primary completion
September 2026
Age range
30 Years and older
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
zhang hui, Doctor
Xuanwu Hospital, Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.